Euglycemic Ketoacidosis in a non-diabetic patient: a rare adverse effect of sodium-glucose co-transporter type-2 inhibitors. A review based on a case report
Sodium-glucose co-transporter type-2 (SGLT-2) inhibitors (SGLT2i) are increasingly used in clinical practice, with proven benefits in chronic conditions such as diabetes mellitus, heart failure (HF), and chronic kidney disease. Prescription of SGLT2i is a common practice among healthcare providers....
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2025-01-01
|
| Series: | Nefrología Latinoamericana |
| Subjects: | |
| Online Access: | https://www.nefrologialatinoamericana.com/frame_eng.php?id=166 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Sodium-glucose co-transporter type-2 (SGLT-2) inhibitors (SGLT2i) are increasingly used in clinical practice, with proven benefits in chronic conditions such as diabetes mellitus, heart failure (HF), and chronic kidney disease. Prescription of SGLT2i is a common practice among healthcare providers. It is imperative that clinicians can identify and prevent adverse effects of these drugs. Euglycemic ketoacidosis (eKA) is a rare and potentially serious adverse effect of SGLT2i in patients with diabetes; recent reports indicate that this can also occur in non-diabetic patients. We present the case of an elderly non-diabetic female patient who was treated with SGLT2i for HF and developed eKA.
|
|---|---|
| ISSN: | 2444-9032 |